-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$6.00151.05% Upside
Nautilus Biotechnology, Inc. Frequently Asked Questions
-
What analysts cover Nautilus Biotechnology, Inc.?
Nautilus Biotechnology, Inc. has been rated by research analysts at Guggenheim in the past 90 days.